These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1520959)

  • 21. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In vitro action spectrum of a new antifungal agent derived from morpholine: amorolfin].
    Regli P; Ferrari H
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):617-20. PubMed ID: 2797885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of the susceptibility of yeast isolates of clinical interest to five antifungal agents using the E test.
    Linares MJ; Muñoz JF; Solís F; Rodríguez FC; Valero A; Casal M
    Rev Esp Quimioter; 1998 Mar; 11(1):64-9. PubMed ID: 9795292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
    Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E
    J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Establishment and evaluation of microdilution assays for the in vitro sensitivity testing of Aspergillus fumigatus].
    Schmidt A; Schmidt DI
    Arzneimittelforschung; 2000 May; 50(5):495-501. PubMed ID: 10858878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens.
    Otcenásek M; Buchta V
    Mycopathologia; 1994 Dec; 128(3):135-7. PubMed ID: 7739727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of reduced oxygen on the antifungal susceptibility of clinically relevant aspergilli.
    Binder U; Maurer E; Lackner M; Lass-Flörl C
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1806-10. PubMed ID: 25547350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro susceptibility of Aspergillus spp. to dithiocarbamate organoruthenium compounds.
    Nogueira LJ; de Resende MA; Oliveira SR; de Araújo MH; Magalhães TF; de Oliveira MB; Martins CV; Lopes MT; Araújo e Silva AC; Donnici CL
    Mycoses; 2011 Sep; 54(5):e323-9. PubMed ID: 20557461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New antifungal compounds from Aspergillus terreus isolated from desert soil.
    Awaad AS; Nabilah AJ; Zain ME
    Phytother Res; 2012 Dec; 26(12):1872-7. PubMed ID: 22422648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The susceptibility of Aspergillus and Penicillium to recent antimycotics].
    Macura AB; Pawlik B; Szczepko I
    Wiad Parazytol; 2000; 46(1):157-62. PubMed ID: 16886366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antifungal activity of 2-(3,4-dimethyl-2,5-dihydro-1H-pyrrol-2-yl)-1-methylethyl pentanoate, a dihydropyrrole derivative.
    Dabur R; Chhillar AK; Yadav V; Kamal PK; Gupta J; Sharma GL
    J Med Microbiol; 2005 Jun; 54(Pt 6):549-552. PubMed ID: 15888463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Mediterranean red alga Asparagopsis taxiformis has antifungal activity against Aspergillus species.
    Genovese G; Leitner S; Minicante SA; Lass-Flörl C
    Mycoses; 2013 Sep; 56(5):516-9. PubMed ID: 23437896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of sugar and amino acid supplementation on Aureobasidium pullulans NRRL 58536 antifungal activity against four Aspergillus species.
    Prasongsuk S; Ployngam S; Wacharasindhu S; Lotrakul P; Punnapayak H
    Appl Microbiol Biotechnol; 2013 Sep; 97(17):7821-30. PubMed ID: 23828601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida.
    Qiao J; Gao P; Jiang X; Fang H
    Ann Clin Microbiol Antimicrob; 2013 Dec; 12():37. PubMed ID: 24314136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advancement in infection control of opportunistic pathogen (Aspergillus spp.): adjunctive agents.
    Ruhil S; Balhara M; Dhankhar S; Kumar M; Kumar V; Chhillar AK
    Curr Pharm Biotechnol; 2013; 14(2):226-32. PubMed ID: 23360263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antifungal resistance in Aspergillus.
    Chandrasekar PH
    Med Mycol; 2005 May; 43 Suppl 1():S295-8. PubMed ID: 16110823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms and clinical significance of antifungal resistance.
    Bille J
    Int J Antimicrob Agents; 2000 Nov; 16(3):331-3. PubMed ID: 11091057
    [No Abstract]   [Full Text] [Related]  

  • 38. The optimal wavelength of spectrophotometric broth microdilution antifungal susceptibility test for flucytosine and three azoles.
    Lee JY; Lee EJ; Kim SH; Jeong HS; Oh SH; Kim HR; Lee JN; Chang CL; Kho WG; Shin JH
    Korean J Lab Med; 2009 Aug; 29(4):324-30. PubMed ID: 19726895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aspergilli Response to Benzalkonium Chloride and Novel-Synthesized Fullerenol/Benzalkonium Chloride Nanocomposite.
    Unković N; Ljaljević Grbić M; Stupar M; Vukojević J; Janković V; Jović D; Djordjević A
    ScientificWorldJournal; 2015; 2015():109262. PubMed ID: 26295057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of purines and pyrimidines on the fungistatic activity of 5-fluorocytosine in Aspergillus species.
    Wagner GE; Shadomy S
    Antimicrob Agents Chemother; 1977 Feb; 11(2):229-33. PubMed ID: 848925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.